Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 1212

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 9A
Chunk 1212
---
 patents and trademarks, all of which are finite-lived, were as follows:

 SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS

    March 31, 2025  
    March 31, 2024 
  
    Patents 
    $3,870,057  
    $3,870,057 
  
    Trademarks 
     26,142  
     26,142 
  
    Total at cost 
     3,896,199  
     3,896,199 
  
    Accumulated Amortization 
     (3,872,474) 
     (3,866,100)
  
    Patents and trademarks, net 
    $23,725  
    $30,099 

For
the years ended March 31, 2025 and 2024, amortization expenses was $6,374
and $8,550,
respectively. The annual amortization expense will be $6,374 for each of the next three years, from 2026 through 2028, and $4,603
in 2029, whereby the net intangible assets will be fully amortized.

    F-13

NOTE
7 – LICENSING AGREEMENTS

The
components of licensing agreements, all of which are finite-lived, were as follows:

 SCHEDULE
OF LICENSING AGREEMENTS

    March 31, 2025  
    March 31, 2024 
  
     License Agreement 
    $2,000,000  
    $- 
  
    Accumulated Amortization 
     (50,000) 
     - 
  
    Total net 
    $1,950,000  
    $- 

In
February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their Precise PRP
(Platelet-Rich Plasma) for both canine and equine products. The exclusive licensing agreement is a 5
five-year agreement whereby the Company paid an initial licensing fee of $2,000,000,
which was paid in a combination of $500,000 cash,
$1,000,000 in
stock issuances and $500,000 in
future contract payments, which is included in accrued expenses as of March 31, 2025. The licensing fee will be amortized over sixty
(60)
months, the term of